Tuesday, June 25, 2013
Biopharmaceutical AmVac has announced that the E.U. approved two grant applications under the seventh framework program (FP7) for the development of vaccines against flu and leishmaniasis. The projects are joint initiatives of AmVac, other European companies and research institutes with expertise in vaccine design and development. Total funding for all participating partners is approximately $7.8 million and $7.2 million, respectively, over five years. Within the funding periods, both vaccines are expected to complete phase I clinical trials.